Proof-of-concept (PoC) Study of APD515

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to look at the effectiveness of a drug called APD515, designed to be applied to the lining inside the mouth, at relieving dryness of the mouth. Study will compare one week of treatment with APD515 to one week of treatment with matching placebo to see which has better effect on patient's mouth dryness, according to their own score.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00003139

Head and Neck Cancer Oral Complications

COMPLETED PHASE3

A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer

NCT02941276

Xerostomia Head and Neck Neoplasms

COMPLETED NA

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

NCT00017511

Head and Neck Cancer Oral Complications Radiation Toxicity

COMPLETED PHASE3

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00656513

Head and Neck Cancer Xerostomia

COMPLETED PHASE2/PHASE3

Blinded Dry Mouth Spray Crossover Study

NCT04608773

Xerostomia Head and Neck Cancer Xerostomia Following Radiotherapy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xerostomia in Advanced Cancer Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APD515

Active APD515 treatment 20 mg qds for 7 days

Group Type EXPERIMENTAL

APD515

Intervention Type DRUG

20 mg oromucosal-oral administration qds for 7 days

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

qds for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APD515

20 mg oromucosal-oral administration qds for 7 days

Intervention Type DRUG

Placebo

qds for 7 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥ 18 years
* Able and willing to give written informed consent.
* Confirmed primary neoplasm at any site (apart from non-melanoma skin cancers), for which first-line cytotoxic therapy has been completed more than one month prior to study entry. Ongoing palliative, hormonal, cytostatic or "targeted" (e.g., monoclonal antibody, tyrosine kinase inhibitor, etc) therapy is permitted, provided that the risk of oral mucositis in the subject is not judged to be significant.
* Subjective complaint of dry mouth, ongoing for at least two weeks prior to study entry.
* Capacity for salivary stimulation, as demonstrated by stimulated whole saliva flow rate \> unstimulated whole saliva flow rate.
* Karnofsky performance score ≥ 60% or ECOG performance status ≤ 2.
* Adequate renal and hepatic function and hydration status:

* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5 \* upper limit normal (ULN);
* Serum urea \< 1.5 \* ULN and serum urea:creatinine ratio \< 100 (where urea and creatinine expressed in the same units);
* Plasma sodium ≤ ULN.
* Adequate haematological function:

* Haemoglobin ≥ 9 g/dL;
* White blood count ≥ 1.0 \* 10\^9/L;
* Platelet count ≥ 50 \*x 10\^9/L.
* For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards.

Exclusion Criteria

* Confirmed diagnosis of Sjögren's syndrome.
* Prior radiotherapy for head \& neck cancer, or other substantial doses of radiation delivered to the area of the mouth or salivary glands.
* Significant, symptomatic disease of the oral cavity, including oral candidosis or oral mucositis.
* Allergy to active ingredient or any of the excipients of APD515.
* Use of oral or topical (including ocular) pilocarpine or cevimeline in the two weeks prior to enrolment.
* Concomitant use of procainamide, quinidine or ganglionic blocking agents such as mecamylamine, pentolinium and trimethaphan.
* Intestinal or urinary obstruction.
* Myocardial infarction or intestinal anastomosis within the previous 6 months.
* Participation in an investigational drug or device study within 1 month prior to study entry.
* For female subjects only, a positive pregnancy test.
* Any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No